CIT and Biomodels claim the synergy derived from this alliance will enable the two companies to provide their clients with a comprehensive and seamless program of pre-clinical drug development, as well as new high-content testing approaches.
The two companies will begin their relationship with integrated packages of services that offer clients a seamless program of preclinical drug development.
CIT CSO Roy Forster said the company is very excited about working with Biomodels especially because of its ability to generate customized preclinical efficacy models.
"Working hand in hand with Biomodels, we will further enrich their understanding of the efficacy and best therapeutic deployment of new drugs and bring these benefits to our clients," Forster said.
CIT CEO Sophie Baratte said the company’s US affiliate, CITox Inc, is responsible for setting up this agreement, a clear affirmation of CIT’s presence in the US and of the proximity to US clients.
"Through this alliance, CIT and Biomodels are offering early testing capabilities in the US that we will transfer smoothly into preclinical development services in our French facility," Baratte said.